DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

STEP UP trial results

Adults with obesity without diabetes.

Wegovy injection
Phase
Phase 3b
Follow-up
72 weeks
Randomised
1,407
Sponsor
Novo Nordisk
Publication
The Lancet Diabetes & Endocrinology · 2025

Double-blind, active- and placebo-controlled. Treatment-policy estimand.

Mean body weight change at 72 weeks
  • Semaglutide 7.2 mg−18.7%
  • Semaglutide 2.4 mg−15.6%
  • Placebo−3.9%
Mean body weight change at 72 weeks
Trial armResult
Semaglutide 7.2 mg−18.7%
Semaglutide 2.4 mg−15.6%
Placebo−3.9%
Gastrointestinal adverse events
Trial armResult
Semaglutide 7.2 mg70.8%
Semaglutide 2.4 mg61.2%
Placebo42.8%

Safety. Dysaesthesia was reported in 22.9%, 6.0% and 0.5% of the respective groups.

Published paper PubMed abstract NCT05646706